C4 Therapeutics, Inc. — Director's Dealing 2021

Mar 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-03-12

Reporting Person: Dubin Glenn (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-12	Stock Option (Right to Buy)	$44.64	A	41200	Acquired	2031-03-11	Common Stock (41200)	Direct

Footnotes

F1: One-third of this option shall vest and become exercisable on March 12, 2022, with the remainder vesting in eight equal quarterly installments thereafter.